Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults-Reference-Cited by-同舟云学术

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

Published:2023-02-16 Issue:7 Volume:388 Page:609-620
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Falsey Ann R.¹,Williams Kristi¹,Gymnopoulou Efi¹,Bart Stephan¹,Ervin John¹,Bastian Arangassery R.¹,Menten Joris¹,De Paepe Els¹,Vandenberghe Sjouke¹,Chan Eric K.H.¹,Sadoff Jerald¹,Douoguih Macaya¹,Callendret Benoit¹,Comeaux Christy A.¹,Heijnen Esther¹

Affiliation:

1. From the University of Rochester School of Medicine, Rochester, NY (A.R.F.); Janssen Vaccines and Prevention, Leiden, the Netherlands (K.W., A.R.B., J.S., M.D., B.C., C.A.C., E.H.); Janssen Infectious Diseases, Beerse, Belgium (E.G., J.M., E.D.P., S.V.); Trial Professionals Consultant Group, Woodstock, MD (S.B.); AMR Kansas City, Kansas City, MO (J.E.); and Janssen Global Services, Raritan, NJ (E.K.H.C.).

Funder

Janssen Vaccines & Prevention B.V.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2207566

Reference45 articles.

1. Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old

2. Respiratory Syncytial Virus–Associated Hospitalizations Among Adults With Chronic Medical Conditions

3. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults